Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Biofrontera (BFRA) stocks in Canada

Learn how to easily invest in Biofrontera stocks.

Biofrontera is a biotechnology business based in the US. Biofrontera stocks (BFRA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.25 – a decrease of 4.68% over the previous week. Biofrontera employs 149 staff and has a trailing 12-month revenue of around $28 million.

How to buy shares in Biofrontera

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BFRA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Biofrontera stock price (NASDAQ:BFRA)

Use our graph to track the performance of BFRA stocks over time.

Biofrontera shares at a glance

Information last updated 2022-01-24.
Latest market close$2.85
52-week range$2.48 - $8.96
50-day moving average $3.59
200-day moving average $5.32
Wall St. target price$8.50
PE ratio N/A
Dividend yield N/A (0.37%)
Earnings per share (TTM) $-0.63

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Biofrontera stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Biofrontera price performance over time

Historical closes compared with the close of $2.85 from 2022-01-25

1 week (2022-01-19) -4.68%
1 month (2021-12-23) -18.57%
3 months (2021-10-22) -51.69%
6 months (2021-07-26) -56.09%
1 year (2021-01-26) -63.65%
2 years (2020-01-24) -74.67%
3 years (2019-01-25) 13.16
5 years (2017-01-22) N/A

Is Biofrontera under- or over-valued?

Valuing Biofrontera stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biofrontera's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biofrontera's EBITDA

Biofrontera's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 million.

The EBITDA is a measure of a Biofrontera's overall financial performance and is widely used to measure a its profitability.

Biofrontera financials

Revenue TTM $28 million
Gross profit TTM $26.8 million
Return on assets TTM -10.51%
Return on equity TTM -124.08%
Profit margin -55.98%
Book value $0.76
Market capitalisation $84.4 million

TTM: trailing 12 months

Biofrontera share dividends

We're not expecting Biofrontera to pay a dividend over the next 12 months.

Biofrontera share price volatility

Over the last 12 months, Biofrontera's shares have ranged in value from as little as $2.48 up to $8.96. A popular way to gauge a stock's volatility is its "beta".

BFRA.US volatility(beta: 1.57)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 1.5711. This would suggest that Biofrontera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Biofrontera overview

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co.

Stocks similar to Biofrontera

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site